Source comparison
CJC-1295 No DAC vs Mod GRF Ipamorelin: Formulation Comparison
CJC-1295 No DAC Modified GHRH (1–29) with 4 substitutions ~30 minutes GHRH receptor (pituitary somatotrophs) 100–200 mcg per injection, 1–3x daily Identical to Mod GRF. Naming preference only. Short half-life requires multiple daily doses for sustained researc
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC
- Modified GHRH (1–29) with 4 substitutions
- ~30 minutes
- GHRH receptor (pituitary somatotrophs)
- 100–200 mcg per injection, 1–3x daily
- Identical to Mod GRF. Naming preference only. Short half-life requires multiple daily doses for sustained research coverage.
- Modified GRF (1-29)
- Identical to CJC-1295 No DAC. Academic naming convention. Preferred in published literature. Same synthesis cost and stability profile.
- Ipamorelin
- Synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2)
- ~2 hours
- Ghrelin receptor (GHS-R1a)
- 100–200 mcg per injection, dosed with GHRH analogue
- Selective ghrelin mimetic. No cortisol or prolactin elevation at research doses. Synergises with GHRH analogues for 3× GH pulse amplitude vs monotherapy.
- CJC-1295 WITH DAC
- Modified GHRH (1–29) + albumin-binding linker
- 6–8 days
- GHRH receptor (sustained binding via albumin reservoir)
- 600–1000 mcg once weekly
- Long-acting version. Fundamentally different pharmacokinetics. Produces sustained baseline GH elevation, not pulsatile release. Not interchangeable with No DAC version.